2012 News and Events
VESSIX VASCULAR TO PRESENT V2 RENAL DENERVATION SYSTEM™ FOR HYPERTENSION AT TRenD WORKSHOP 2012

Laguna Hills, CA, February 13, 2012 - Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that it will make its first detailed public presentation of preclinical data relating to its new V2 Renal Denervation System™ on Saturday, February 18, 2012 at the TRenD Workshop 2012, in Frankfurt, Germany.

The presentation, titled "Percutaneous RF balloon-mediated renal denervation in under a minute: The V2 System by Vessix," will be made by James R. Margolis, M.D., a luminary in the field of interventional cardiology, during a session focused on emerging technologies for renal denervation.

Renal denervation is a percutaneous, catheter-based approach that disrupts renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

Dr. Margolis commented, “Vessix’s pre-clinical data is the most robust I have seen in the field of renal denervation for hypertension. The data provides significant angiographic and histological evidence of safety and also effectiveness in reducing kidney norepinephrine levels – a surrogate for reduction of blood pressure in humans. The Vessix RF balloon catheter technology promises to place a very familiar tool in the hands of interventionalists and allow therapy to be safely delivered in seconds. I look forward to seeing the results of the upcoming multi-center international clinical study set to begin in Europe later this month.”

Vessix's V2 Renal Denervation System for the treatment of drug resistant hypertension is an over the wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the delivery of RF inside the renal artery. The patented catheter connects to a proprietary low power bipolar RF generator. After inflation in the artery, the balloon catheter’s RF energy is activated for 30 seconds resulting in the disruption of the renal nerves located in the adventitia that surround the renal artery.

About the Vessix V2 Renal Denervation System

  • Therapy is delivered via a balloon catheter that is quite familiar to interventional cardiologists thereby increasing the usability and safety profile of the device.
  • The V2 balloon catheter occludes blood flow to the renal artery during the 30 second RF therapy delivery allowing for directed and highly controlled flow of energy. Consequently, the V2 is significantly faster - by an order of magnitude - than the only other competitively marketed renal denervation system that takes approximately 30 minutes to deliver treatment to each renal artery.
  • Rapid RF treatment time greatly increases the efficiency of the renal denervation procedure and promises additional safety benefits to the patient in terms of lower exposure to radiation, less use of contrast dye and lower renal toxicity.

About Vessix Vascular, Inc. – Founded in 2003, Vessix is a venture backed privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. Vessix is backed by European and U.S. investors including NeoMed Management, Edmond de Rothschild and OrbiMed Advisors. The Company’s initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries. For more information on Vessix Vascular, please visit the Company’s website at www.vessixvascular.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

 


 
$23 Million Financing Complete and Corporate Name Changed to Vessix Vascular

VESSIX VASCULAR COMPLETES $23 MILLON FINANCING

ROUND LED BY EDMOND DE ROTHSCHILD INVESTMENT PARTNERS AND ORBIMED ADVISORS

Laguna Hills, CA, August 3, 2011 – Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.), a developer of novel percutaneous radiofrequency (RF) balloon catheter technology announced today that it has completed a $23 million Series B preferred stock financing. The lead investor in the financing round was Edmond de Rothschild Investment Partners (EdRIP) of Paris, France. Also participating in the financing was NY-based OrbiMed Advisors, CDF Dinova Venture Partners of Hong Kong along with existing investors NeoMed Management and Christopher Weil & Company. Subsequent to the close of the transaction, Raphael Wisniewski of EdRIP and Vince Burgess of OrbiMed have been appointed to the Vessix Board of Directors. Use of proceeds from the financings will provide working capital to accelerate product development initiatives and funding for a series of multi-center clinical trials to further expand clinical indications for the Company’s patented RF balloon catheter technology. In conjunction with the financing, Vessix Vascular established a European subsidiary based in Paris with a view toward supporting its European clinical studies and anticipated commercial product launches.

Raymond W. Cohen, Chief Executive Officer of Vessix said, “We are encouraged that this group of world class investors and strategic partners has recognized the potential of the Vessix technology and the large patient populations that could benefit from commercialization of our products. Over the next year, we intend to move into a number of new clinical applications where our technology is well suited.”

About NeoMed Management - NeoMed Management is an international investment firm, exclusively focusing on the healthcare and life science industry. Founded in 1996, NeoMed has established four funds, with total committed capital exceeding $200 million.  NeoMed invests in early-stage life science companies with outstanding growth prospects. For more information please visit: www.neomed.net

About EdRIP - Paris-based Edmond de Rothschild Investment Partners is dedicated to investments into privately owned companies. It has currently more than €800 million under management invested primarily as life sciences venture capital and growth capital. The life sciences team consists of seven professionals bringing together over 30 years of experience in the life science industry and more than 50 years of private equity and venture capital experience. The team has approximately €220 million under management, and raised its most recent fund, €150 million BioDiscovery 3 fund, in 2008. Edmond de Rothschild Investment Partners is part of La Compagnie Financière Edmond de Rothschild. For more information please visit: www.edrip.fr

About OrbiMed Advisors, LLC - OrbiMed Advisors is the largest healthcare-dedicated fund manager in the world.  With approximately $5 billion under management and offices in New York, San Francisco, Tel Aviv, Shanghai, and Mumbai, OrbiMed offers the global resources to be an exceptional long term partner for its portfolio companies. For more information, please visit: www.OrbiMed.com

About Christopher Weil & Company, Inc - Christopher Weil & Company, Inc. is a San Diego-based FINRA-member Broker-Dealer and SEC Registered Investment Advisor that, together with affiliates, has sponsored and managed over fifty private equity funds formed to invest in real estate, oil/gas operations, small business equity, venture capital and specialty securities portfolios. For more information please visit: www.cweil.com

About Vessix Vascular, Inc. - Vessix was initially founded in 2003 as Minnow Medical, Inc. Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. For more information on Vessix Vascular, please visit the Company’s website at www.vessixvascular.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

 

# # # #